



# emami limited

CIN No. : L63993WB1983PLC036030

Regd. Office : 687, Anandapur, Emami Tower, E.M. Bypass, Kolkata 700 107  
website : www.emamiltltd.in

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED & HALF YEAR ENDED 30th SEPTEMBER, 2014

Consolidated						S.N.	PARTICULARS	Standalone					
Reviewed			Audited					Reviewed			Audited		
Quarter Ended		Half Year Ended	Year Ended		Year Ended			Quarter Ended		Half Year Ended	Year Ended		
30.09.2014	30.06.2014	30.09.2013	30.09.2014	30.09.2013	31.03.2014	30.09.2014	30.06.2014	30.09.2013	30.09.2014	30.09.2013	31.03.2014		
48,960	48,173	40,674	97,133	79,039	1,82,077	1.	<b>Income from Operations:</b>	44,410	44,204	37,434	88,614	74,489	1,70,508
							(a) Net Sales/ Income from Operation (Net of Excise Duty)						
							(b) Other Operating Income						
48,960	48,173	40,674	97,133	79,039	1,82,077		<b>Total Income from Operations (Net)</b>	44,410	44,204	37,434	88,614	74,489	1,70,508
							<b>Expenses :</b>						
16,008	13,061	13,343	29,069	22,916	55,594		(a) Cost of Materials Consumed	15,292	12,517	13,133	27,809	22,659	54,397
3,342	3,717	2,971	7,059	7,685	14,996		(b) Purchases of Finished Goods	3,043	3,610	2,318	6,653	6,667	13,421
(2,803)	1,801	(1,359)	(1,002)	129	(2,562)		(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(2,613)	1,682	(1,365)	(931)	151	(2,418)
4,440	4,195	3,676	8,635	7,081	13,902		(d) Employee Benefits Expense	3,909	3,705	3,280	7,614	6,337	12,368
899	441	3,141	1,340	6,258	9,615		(e) Depreciation and Amortisation Expense	835	382	3,083	1,217	6,151	9,380
-	-	(2,552)	-	(5,104)	(6,098)		(f) Transfer from General Reserve	-	-	(2,552)	-	(5,104)	(6,098)
9,010	10,284	6,770	19,294	14,003	27,741		(g) Advertisement and Sales Promotion	7,041	8,741	5,843	15,782	12,384	23,736
7,641	7,615	6,540	15,256	12,571	28,276		(h) Other Expenses	6,998	7,071	6,046	14,069	11,738	26,283
38,537	41,114	32,530	79,651	65,539	1,41,464		<b>Total Expenses</b>	34,505	37,708	29,786	72,213	60,983	1,31,069
10,423	7,059	8,144	17,482	13,500	40,613		<b>Profit/ (Loss) from Operations before Other Income, Finance Costs and Exceptional Items (1-2)</b>	9,905	6,496	7,648	16,401	13,506	39,439
(264)	(156)	(178)	(420)	(448)	(309)		4. Foreign Exchange (Gain)/ Loss	(276)	(146)	(186)	(422)	(431)	(311)
1,223	2,077	1,643	3,300	3,155	6,218		5. Other Income	1,216	2,088	1,642	3,304	3,153	6,246
11,910	9,292	9,965	21,202	17,103	47,140		<b>Profit/ (Loss) from Ordinary Activities before Finance Costs and Exceptional Items (3-4+5)</b>	11,397	8,730	9,476	20,127	17,090	45,996
132	81	139	213	256	538		7. Finance Costs	127	75	88	202	165	389
11,778	9,211	9,826	20,989	16,847	46,602		<b>Profit/ (Loss) from Ordinary Activities after Finance Costs but before Exceptional Items (6-7)</b>	11,270	8,655	9,388	19,925	16,925	45,607
-	-	-	-	-	889		9. Exceptional Items	-	-	-	-	-	428
11,778	9,211	9,826	20,989	16,847	45,713		<b>Profit/ (Loss) from Ordinary Activities before Tax (8-9)</b>	11,270	8,655	9,388	19,925	16,925	45,179
2,502	2,130	1,831	4,632	2,785	5,470		10. Tax Expense	2,358	2,079	1,795	4,437	2,730	5,356
9,276	7,081	7,995	16,357	14,062	40,243		<b>Net Profit/ (Loss) from Ordinary Activities after Tax (10-11)</b>	8,912	6,576	7,593	15,488	14,195	39,823
-	-	-	-	-	-		13. Extraordinary Item (Net of Tax Expense)	-	-	-	-	-	-
9,276	7,081	7,995	16,357	14,062	40,243		<b>Net Profit/ (Loss) for the Period (12-13)</b>	8,912	6,576	7,593	15,488	14,195	39,823
-	-	-	-	-	-		14. Net Profit/ (Loss) of Associates	-	-	-	-	-	-
-	(1)	(1)	(1)	(2)	(4)		16. Minority Interest	-	-	-	-	-	-
9,276	7,082	7,996	16,358	14,064	40,247		<b>Net Profit/ (Loss) after Taxes, Minority Interest and Share of Profit/ (Loss) of Associates (14+15-16)</b>	8,912	6,576	7,593	15,488	14,195	39,823
2,270	2,270	2,270	2,270	2,270	2,270		18. Paid - up Equity Share Capital (Face Value ₹1 per Share)	2,270	2,270	2,270	2,270	2,270	2,270
							19. Reserves excluding Revaluation Reserves as per Balance Sheet of previous Accounting Year						90,599
							20. Earnings per Share (before Extraordinary Items) (Face Value of ₹1 each) (not Annualised) :						
4.09	3.12	3.52	7.21	6.20	17.73		(a) Basic	3.93	2.90	3.35	6.82	6.25	17.55
4.09	3.12	3.52	7.21	6.20	17.73		(b) Diluted	3.93	2.90	3.35	6.82	6.25	17.55
4.09	3.12	3.52	7.21	6.20	17.73		(a) Basic	3.93	2.90	3.35	6.82	6.25	17.55
4.09	3.12	3.52	7.21	6.20	17.73		(b) Diluted	3.93	2.90	3.35	6.82	6.25	17.55
							<b>A. PARTICULARS OF SHAREHOLDING</b>						
							<b>1. Public Shareholding</b>						
6,18,78,764	6,18,78,764	6,18,78,764	6,18,78,764	6,18,78,764	6,18,78,764		i) Number of Shares	6,18,78,764	6,18,78,764	6,18,78,764	6,18,78,764	6,18,78,764	6,18,78,764
27.26	27.26	27.26	27.26	27.26	27.26		ii) Percentage of Shares	27.26	27.26	27.26	27.26	27.26	27.26
							<b>2. Promoters and Promoter Group Shareholding</b>						
							<b>a. Pledged/ Encumbered</b>						
3,30,74,268	3,61,44,668	1,95,91,618	3,30,74,268	1,95,91,618	3,09,78,618		i) Number of Shares	3,30,74,268	3,61,44,668	1,95,91,618	3,30,74,268	1,95,91,618	3,09,78,618
20.03	21.89	11.87	20.03	11.87	18.76		ii) Percentage of Shares	20.03	21.89	11.87	20.03	11.87	18.76
							(As a percentage of total Shareholding of Promoter and Promoter Group)						
14.57	15.93	8.63	14.57	8.63	13.65		iii) Percentage of Shares	14.57	15.93	8.63	14.57	8.63	13.65
							(As a percentage of total Share Capital of the Company)						
13,20,14,587	12,89,44,187	14,54,97,237	13,20,14,587	14,54,97,237	13,41,10,237		<b>b. Non-Encumbered</b>	13,20,14,587	12,89,44,187	14,54,97,237	13,20,14,587	14,54,97,237	13,41,10,237
79.97	78.11	88.13	79.97	88.13	81.24		i) Number of Shares	79.97	78.11	88.13	79.97	88.13	81.24
							ii) Percentage of Shares						
							(As a percentage of total Shareholding of Promoter and Promoter Group)						
58.16	56.81	64.10	58.16	64.10	59.09		iii) Percentage of Shares	58.16	56.81	64.10	58.16	64.10	59.09
							(As a percentage of total Share Capital of the Company)						

PARTICULARS		30.09.2014
<b>B. INVESTOR COMPLAINTS</b>		
Pending at the beginning of the quarter		0
Received during the quarter		3
Disposed off during the quarter		3
Remaining unresolved at the end of the quarter		0

Statement of Assets & Liabilities					
Consolidated		S.N.	Particulars	Standalone	
Reviewed	Audited			Reviewed	Audited
As at	As at			As at	As at
30.09.2014	31.03.2014			30.09.2014	31.03.2014
		<b>A. EQUITY AND LIABILITIES</b>			
		<b>1 Shareholders' Fund</b>			
2,270	2,270	Share Capital		2,270	2,270
96,651	90,942	Reserves and Surplus		95,389	90,599
<b>98,921</b>	<b>93,212</b>			<b>97,659</b>	<b>92,869</b>
		<b>2 Minority Interest</b>			
		<b>3 Non-Current Liabilities</b>			
1,800	1,745	Long-Term Borrowings		1,540	1,503
891	479	Deferred Tax Liabilities (Net)		891	479
1,512	1,186	Other Long Term Liabilities		1,506	1,181
2,144	1,713	Long-Term Provisions		2,052	1,648
<b>6,347</b>	<b>5,123</b>			<b>5,989</b>	<b>4,811</b>
		<b>4. Current Liabilities</b>			
5,949	437	Short-Term Borrowings		5,801	130
23,870	14,297	Trade Payables		17,598	11,461
5,764	5,045	Other Current Liabilities		5,557	4,688
1,411	12,114	Short-Term Provisions		1,257	12,088
<b>36,994</b>	<b>31,893</b>			<b>30,213</b>	<b>28,367</b>
<b>1,42,262</b>	<b>1,30,229</b>	<b>TOTAL</b>		<b>1,33,861</b>	<b>1,26,047</b>
		<b>B ASSETS</b>			
		<b>1. Non-Current Assets</b>			
44,449	40,777	Net Fixed Assets		41,812	38,210
-	-	Goodwill on Consolidation		-	-
662	662	Non-Current Investments		709	709
5,794	4,218	Long-Term Loans and Advances		5,586	4,009
2	1	Other Non-Current Asset		2	1
<b>50,907</b>	<b>45,658</b>			<b>48,109</b>	<b>42,929</b>
		<b>2. Current Assets</b>			
31,905	28,922	Current Investments		31,904	28,922
17,147	14,115	Inventories		16,539	13,662
8,863	7,930	Trade Receivables		6,429	7,522
23,398	26,996	Cash and Cash Equivalents		21,438	26,484
10,042	6,608	Short-Term Loans and Advances		9,442	6,528
<b>91,355</b>	<b>84,571</b>			<b>85,752</b>	<b>83,118</b>
<b>1,42,262</b>	<b>1,30,229</b>	<b>TOTAL</b>		<b>1,33,861</b>	<b>1,26,047</b>

### NOTES :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 29th October, 2014. The Statutory Auditors of the company have carried out Limited Review of these results and the results are being published in accordance with clause 41 of the Listing Agreement.
- The unaudited consolidated financial results comprise of Emami Limited and its subsidiaries viz. Emami UK Limited, Emami International FZE (including Emami Overseas FZE, U.A.E and Pharma Derm S.A.E.Co. Egypt, subsidiary and step down subsidiary respectively of Emami International FZE) and Emami Bangladesh Limited.
- The Company has changed the method of providing depreciation on assets of Vapi, Masat and Dongari units from written down value to straight line method based on useful lives as prescribed in Schedule II of the Companies Act, 2013 ("the Act"). As prescribed under Accounting Standard 6 - Depreciation Accounting, the change has been made with retrospective effect, on account of which excess depreciation of ₹ 477 lacs charged upto 31st March 2014 has been written back and adjusted against depreciation in the first quarter of current financial year. Hence, the depreciation charged for the half year ended is lower and profit after tax is higher by ₹ 12.16 lacs due to the aforementioned change. An amount of ₹ 77 lacs (net of deferred tax) has been recognized in the opening balance of retained earnings for the assets where remaining useful life as per Schedule II is Nil. Depreciation on all other assets has been provided in compliance with Schedule II of the Act.
- The Board of Directors at its meeting held on 17th September 2014, recommended an Interim Dividend of 400%, i.e. ₹ 4/- per equity share having paid up value of ₹ 1/- each. The Company had fixed 22nd September 2014 as the Record Date for the purpose of determining shareholders entitled to receive the said Interim Dividend & the same has been paid accordingly.
- As the Company's business activity falls within a single primary business segment, viz. "Personal and Healthcare", the disclosure requirements of Accounting Standard - 17 "Segment Reporting", notified in Companies (Accounting Standards) Rules, 2006 are not applicable.
- Comparative figures have been rearranged / regrouped wherever necessary.
- These Financial Results are available on the company's website at <http://www.emamiltltd.in>

For and on behalf of the Board

Place : Kolkata  
Date : 29th October, 2014

**Sushil Kr. Goenka**  
Managing Director

## Making people Healthy & Beautiful, Naturally



**BOROPLUS**  
India's No. 1 Antiseptic Cream

**Navratna**  
Thanda Thanda Cool Cool

**FAIR AND HANDSOME**  
World's No.1 Fairness Cream for Men

**ZANDU**  
Desh ka balm

**FAST RELIEF**  
Dard mitaye chutki mein

**MENTHO PLUS**  
Dus siron ka dard bhagaye

**She**  
License to live a normal life